Physician profile

Manjari Nathan

Pulmonary Disease · Walnut Creek, CA

NPI 1033386503

$8,505.92

in general payments reported to CMS, 2019-2025

36 companies · $2,607 in 2025

The $2,607 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,046.74
Travel and Lodging$929.41
Education$383.43

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Genzyme Corporation $2,262.40 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $1,287.29 2019-2025 Ofev, Jascayd
Medical Device Business Services, INC. $1,028.54 2025 Monarch
Astrazeneca Pharmaceuticals LP $782.53 2019-2025 Fasenra, Airsupra, Breztri
Glaxosmithkline, LLC. $469.79 2019-2025 Trelegy Ellipta, Nucala
Actelion Pharmaceuticals US, INC. $271.59 2019-2022
Inspire Medical Systems, INC. $233.48 2024-2025 Inspire
Jazz Pharmaceuticals INC. $229.21 2023-2024
Harmony Biosciences LLC $177.22 2021-2024
Sanofi-Aventis U.S. LLC $167.74 2023-2025
Merck Sharp & Dohme LLC $160.71 2020-2025 Zerbaxa, Recarbrio
Janssen Pharmaceuticals, INC $144.82 2019-2024 Xarelto
Takeda Pharmaceuticals U.S.A., INC. $128.88 2020-2023 Glassia
Advanced Respiratory, INC $104.03 2019-2021
Fisher & Paykel Healthcare INC $94.20 2024-2025 Fisher & Paykel Healthcare
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $87.56 2022-2025 Tezspire
Vanda Pharmaceuticals INC. $86.63 2022-2023 Hetlioz
Ethicon INC. $84.54 2021-2022
La Jolla Pharmaceutical Company $76.60 2023-2024 Giapreza
Baxter Healthcare $74.83 2022-2023 Hillrom - Life 2000 Ventilation System
United Therapeutics Corporation $67.53 2025 Tyvaso
Bayer Healthcare Pharmaceuticals INC. $65.54 2020-2022
Abbvie INC. $60.42 2022
Lilly USA, LLC $58.91 2025 Zepbound
Melinta Therapeutics, LLC $43.04 2024 Vabomere, Rezzayo, Kimyrsa
Resmed Corp $42.39 2020-2024
Insmed, INC. $39.29 2024 Arikayce
Philips North America LLC $32.90 2021
Genentech USA, INC. $28.88 2019-2020
Avadel Cns Pharmaceuticals, LLC $28.75 2024 Lumryz
Verona Pharma, INC. $18.00 2025 Ohtuvayre
Apria Healthcare LLC $17.80 2021
Pulmonx Corporation $16.75 2021
Circassia INC. $14.64 2019
Shire North American Group INC $10.84 2019
Itamar Medical INC $7.65 2023 Watchpatone

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Manjari Nathan

$8,505.92

in general payments reported 2019-2025

Years
2019-2025
Top company
Genzyme Corporation
Context
The $2,607 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/273565/manjari-nathan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.